Abstract: Provided is a pharmaceutical composition for preventing or treating cancer, containing, as an active ingredient, an oligopeptide usable in treating cancer. Since an oligopeptide of the presently claimed subject matter has a molecular weight lower than those of antibodies, there are advantages for less concern of an immune response and easily penetrating into tissues, and selectively acting on cancer cells or cancer tissues.
Abstract: Provided are a compound for enhancing anticancer effect of targeted anticancer drugs and chemotherapeutic agents currently in use, more particularly, to an analog compound of the oligopeptide AQTGTGKT and a composition comprising the same, wherein the analog compound exhibits an excellent anticancer effect without any side effects when mixed with an anticancer drug for combined therapy, as compared with a control group and each of single treatment groups, thereby a significant synergistic effect in inhibiting cancer growth is provided, with minimizing side effects including damage to functions and activities that appear in normal tissues, bone marrow dysfunction, gastrointestinal disturbance, alopecia, anticancer drug resistance, and the like. In addition, the oligopeptide has a smaller molecular weight than that of an antibody, and thus causing less concern on immune reaction due to its smaller molecular weight than that of an antibody, and providing advantage of readily permeating into tissue.
Type:
Application
Filed:
March 16, 2022
Publication date:
June 27, 2024
Applicant:
L-BASE CO., LTD.
Inventors:
Do Yong JEON, Chang Hoon MOON, Hyun Hee SHIN, Hye Rim LEE, Jeong Min KIM, Jee Young LEE
Abstract: Provided are an analog compound of an oligopeptide AQTGTGKT, which exhibits an excellent anticancer effect and is stably present in human blood, a pharmaceutical composition including the same as an active ingredient, and a preparation method thereof, wherein the analog compound advantageously exhibits an excellent effect of suppressing the proliferation of cancer cells, has less immune responses, and easily penetrates into tissue due to smaller molecular weights of oligopeptide preparations than those of antibodies, therefore it can be used as a useful anticancer agent for treating cancer.
Abstract: Provided is a pharmaceutical composition for preventing or treating cancer, containing, as an active ingredient, an oligopeptide usable in treating cancer. Since an oligopeptide of the presently claimed subject matter has a molecular weight lower than those of antibodies, there are advantages for less concern of an immune response and easily penetrating into tissues, and selectively acting on cancer cells or cancer tissues.
Abstract: Provided are a polypeptide having the activity of inhibiting autophagy in a cell, a composition for inhibiting autophagy in a cell, and particularly in a tumor cell, containing the polypeptide as an active ingredient, and a pharmaceutical composition containing the polypeptide, and more specifically, a composition for inhibiting autophagy in a cell containing a polypeptide inhibiting the control mechanism of autophagy as an active ingredient, and a pharmaceutical composition for preventing or treating a neoplastic disease or for inhibiting resistance to anticancer agents, containing the polypeptide.
Type:
Application
Filed:
July 31, 2020
Publication date:
November 19, 2020
Applicant:
L-BASE CO., LTD
Inventors:
Do Yong JEON, Chang Hoon MOON, Ji Eun JUNG
Abstract: Provided are a polypeptide having the activity of inhibiting autophagy in a cell, a composition for inhibiting autophagy in a cell, and particularly in a tumor cell, containing the polypeptide as an active ingredient, and a pharmaceutical composition containing the polypeptide, and more specifically, a composition for inhibiting autophagy in a cell containing a polypeptide inhibiting the control mechanism of autophagy as an active ingredient, and a pharmaceutical composition for preventing or treating a neoplastic disease or for inhibiting resistance to anticancer agents, containing the polypeptide.
Type:
Grant
Filed:
May 28, 2018
Date of Patent:
September 8, 2020
Assignee:
L-BASE CO., LTD
Inventors:
Do Yong Jeon, Chang Hoon Moon, Ji Eun Jung
Abstract: A pharmaceutical anticancer or anticancer drug-resistance composition for a cancer cell, containing a CAGE-derived peptide, is provided. The pharmaceutical anticancer composition contains an effective ingredient of the CAGE-derived oligopeptide with SEQ TD NO.1 or SEQ ID NO.2 and reduces anticancer drug resistance or exhibits an anticancer effect. The pharmaceutical anticancer composition can be employed for a new anticancer drug with advanced anticancer activity of itself, as well as improving a remedy effect with an anticancer drug because of effectively reducing cancer cells, which are resistive to an anticancer drug, and anticancer drug resistance of cancer tissues. The oligopeptide as the effective ingredient of the pharmaceutical anticancer composition is hardly concerned with immunity reaction because of small molecular weight, different from an antibody, and advantageous in effectively overcoming general anticancer drugs because of selective activity to a cancer cell or a cancer tissue.
Abstract: Provided are a polypeptide having the activity of inhibiting autophagy in a cell, a composition for inhibiting autophagy in a cell, and particularly in a tumor cell, containing the polypeptide as an active ingredient, and a pharmaceutical composition containing the polypeptide, and more specifically, a composition for inhibiting autophagy in a cell containing a polypeptide inhibiting the control mechanism of autophagy as an active ingredient, and a pharmaceutical composition for preventing or treating a neoplastic disease or for inhibiting resistance to anticancer agents, containing the polypeptide.
Type:
Application
Filed:
May 28, 2018
Publication date:
March 19, 2020
Applicant:
L-BASE CO., LTD
Inventors:
Do Yong JEON, Chang Hoon MOON, Ji Eun JUNG
Abstract: A peptide having eight amino acid sequences derived from cancer-associated gene (CAGE) is described which retains anticancer activity and activity to promote anticancer drug sensitivity of anticancer drug resistant cancer cells. Specifically, a peptide which has an amino acid sequence of SEQ ID NO: 1 (AQTGTGKT) and thus binds to the CAGE protein is disclosed, which inhibits an inter-linkage between CAGE and GSK3?, thus exhibiting anticancer activity and activity to promote anticancer drug sensitivity of anticancer drug resistant cancer cells. A pharmaceutical composition is also disclosed containing the peptide with the amino acid sequence of SEQ ID NO: 1 (AQTGTGKT), for anticancer use or anticancer drug aiding.
Type:
Grant
Filed:
June 16, 2017
Date of Patent:
March 26, 2019
Assignee:
L-BASE CO., LTD.
Inventors:
Doo Il Jeoung, Young Mi Kim, Hyun A Kim
Abstract: A peptide having eight amino acid sequences derived from cancer-associated gene (CAGE) is described which retains anticancer activity and activity to promote anticancer drug sensitivity of anticancer drug resistant cancer cells. Specifically, a peptide which has an amino acid sequence of SEQ ID NO: 1 (AQTGTGKT) and thus binds to the CAGE protein is disclosed, which inhibits an inter-linkage between CAGE and GSK3?, thus exhibiting anticancer activity and activity to promote anticancer drug sensitivity of anticancer drug resistant cancer cells. A pharmaceutical composition is also disclosed containing the peptide with the amino acid sequence of SEQ ID NO: 1 (AQTGTGKT), for anticancer use or anticancer drug aiding.
Type:
Grant
Filed:
November 17, 2017
Date of Patent:
March 19, 2019
Assignee:
L-BASE CO., LTD.
Inventors:
Doo II Jeoung, Young Mi Kim, Hyun A Kim